Carbohydrate-based Antitumor Glycomedicine Development

Carbohydrate-based Antitumor Glycomedicine Development

Cancer constitutes the second leading cause of death globally. Although conventional chemotherapy has been successful to some extent, the main drawbacks of chemotherapy are its poor bioavailability, high-dose requirements, adverse side effects, low therapeutic indices, development of multiple drug resistance, and non-specific targeting. Therefore, scientists are paying more and more attention to antitumor glycomedicine development. Most of the professionals of CD BioGlyco, most with a Ph.D. degree, are highly skilled in carbohydrate-based antitumor glycomedicine development. We are proficient at in vitro and in vivo antitumor activity screening.

Carbohydrates are the most abundant complex biomolecules, which play pivotal roles in many cellular interactions, such as signaling to other cellular molecules or cell surface receptors. A wide range of monosaccharide and oligosaccharide residues are connected by glyosidic linkages to form essential glycoconjugates, including glycoproteins, glycolipids, and glycosylated natural products. Furthermore, the biosynthesis of those glycans is controlled by several enzymes, so any deviation in the structure of cell surface glycans enables them to encode information essential for disease progression. Therefore, carbohydrates, which can induce glycan-mediated interactions, are targeted as pharmaceutical therapeutic agents aimed at treating various pathological diseases.

Aside from carbohydrate-based tumor antigens, cancer cells also contain an increased number of glucose transporters and lectins (GLUTs) on their membrane surface, which can transport or bind carbohydrate moieties, respectively. The demand for increased energy in the proliferation of cancer cells is met by GLUTs, which allow for an increased uptake of glucose at a higher rate than normal cells—a phenomenon commonly referred to as the "Warburg effect". This effect has garnered much attention from the community, as many scientists have designed and developed carbohydrate-based antitumor glycomedicine. In addition, monitoring of in vivo and in vitro anticancer activity of drugs has gained increasing attention.

Carbohydrate-based Antitumor Glycomedicine Development Services

At CD BioGlyco, the development services for carbohydrate-based antitumor glycomedicine involve synthetic carbohydrate anti-tumour glycomedicine and antitumor activity screening. We provide high-quality in vitro and in vivo antitumor activity screening services. For synthetic carbohydrate antitumor vaccines, we provide a range of services including but not limited to:

  • Total syntheses of Globo-H (a hexasaccharide to be localized on tissues in areas where the immune system has restricted access.).
  • Conjugation of acetylated hexasaccharides to keyhole limpet hemocyanin (KLH).
  • Immunization of mice with the Globo-H-KLH conjugate resulted in high-titre IgM and IgG responses against the Globo-H antigen.

Advantages of Us

  • Outstanding carbohydrate-based antitumor glycomedicine development technology.
  • Professional team, high-quality customized services.
  • Extensive experience.
  • The competitive price.

CD BioGlyco has been committed to carbohydrate-based glycomedicine development for many years. We also provide our customers with high-quality, cost-effective, and hassle-free customized in vitro and in vivo antitumor activity screening services. If you are interested in our services, please feel free to contact us, we are looking forward to being your indispensable assistant.

Reference:

  1. Hossain, F.; et al. Developments in carbohydrate-based cancer therapeutics. Pharmaceuticals. 2019, 12(2): 84.
This service is for Research Use Only, not intended for any clinical use.

Christmas

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.